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A B S T R A C T
Purpose: It is believed that a large number of factors inﬂuence feelings of stigma, but their relative
contribution is not yet entirely clear. Most studies to date were conducted using the Epilepsy Stigma
Scale (ESS); only one used a revised version of the ESS (rESS). The following study aims to determine
factors contributing to epilepsy stigma in outpatients with chronic epilepsy in Croatia, and to analyze
some psychometric properties of the Croatian translation of the rESS.
Methods: Alongside standard testing for validity of the scale, a simulation model of the original ESS
(smESS) was created. This model, which does not include a grading Likert 0–3 scale, was compared with
the rESS.
Results: In total, 159 out of 298 subjects (53%) reported feeling stigmatised, with 136 (45%) mild to
moderately and 23 (8%) highly. Internal consistency of the Croatian translation of the rESS was 0.887.
Feelings of stigma were signiﬁcantly associated with age 50 years, younger age of epilepsy onset,
more than 50 seizures to date, generalized tonic–clonic seizures, and a shorter seizure-free period.
Multiple stepwise regression showed number of seizures to date as a signiﬁcant variable (Beta = 0.246).
By adapting data into the smESS signiﬁcant associations with younger age and age of epilepsy onset
were lost. Internal consistency of the smESS was 0.849.
Conclusions: The Croatian translation of the rESS has been proved to be a suitable instrument for
diagnosing epilepsy stigma. The results of our model point to the possibility that the rESS might be more
sensitive than the original ESS.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsy is a condition highly associated with feelings of
stigma.1,2 This is universally true among countries with different
cultural backgrounds.3–6 In Europe, the frequency of epilepsy
patients experiencing stigma is reported as between 31% and
69%.3,4,7–11 It is believed that a large number of factors inﬂuence
feelings of stigma, ranging from social circumstances and seizure
control to psychological traits of individuals with epilepsy. Some of
the important factors seem to be number of seizures and seizure-
free period, compliance with medication, age and age of epilepsy
onset, employment status, level of family functioning, degree of* Corresponding author at: Department of Neurology Sveti Duh University
Hospital Sveti Duh 64, 10000 Zagreb, Croatia. Tel.: +385 1 3712 143;
fax: +385 1 3712 372.
E-mail address: ibielen@kbsd.hr (I. Bielen).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.10.008self-esteem, and experience of anxiety and depression.3,6,7,10–14
However, the relative contribution of these factors to stigma seems
to vary across different European countries.6,15
Many studies addressing the contribution of different factors to
stigma used the Epilepsy Stigma Scale (ESS), ﬁrst described by
Jacoby in 1992,16 and later revised in order to detect more subtle
differences in levels of felt stigma. So far, this revised stigma scale
(rESS) has been used in only one study of subjects with recently
diagnosed epilepsy,11 as a subgroup of patients with epilepsy
included in the SANAD trial.17,18 In all other studies,3,16,19–22
including the most recent one,7,8 the original version of the scale
was used.
Research on epilepsy stigma in Croatia has not yet been
performed. Our initial hypothesis was that the prevalence of
stigmatisation due to epilepsy would be similar to other European
countries, but also that by utilizing the rESS, risk factors for stigma
could be identiﬁed more precisely. Therefore, the aims of this study
were to (1) determine factors contributing to feelings of stigma invier Ltd. All rights reserved.
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psychometric properties of the Croatian translation of the rESS.
Alongside standard testing for validity of the scale, a simulation
model of the original Epilepsy Stigma Scale (smESS) was created.
This model, which does not include a graded Likert 0–3 scale for
each of the questions, was compared with the rESS. With this
approach, we wanted to test the potential advantages of the rESS in
epilepsy stigma research.
2. Methods
2.1. Subjects
Subjects were patients with epilepsy who attended regular
visits as outpatients at one of the three participating hospital-
based epilepsy services for adults in Croatia. Exclusion criteria
were: inability to ﬁll in the provided questionnaire without help,
not taking AEDs and epilepsy that was diagnosed during the
previous 6 months. The data were collected in each of the
afﬁliations over 6 weeks, from the beginning of April until the end
of May 2012.
3. Questionnaire
Subjects were asked to complete a questionnaire containing 9
questions concerning demographic data and clinical features of
their epilepsy, and the revised version of the Epilepsy Stigma Scale
(rESS), translated into Croatian. An ofﬁcial interpreter, together
with the author of this study, has endorsed the Croatian
translation. When completing the rESS, individuals are asked to
respond on a scale of 0–3 (0 = not at all, 1 = yes, maybe, 2 = yes,
probably, 3 = yes, deﬁnitely) whether, because of their epilepsy,
they feel that other people are (1) uncomfortable with them, (2)
treat them as inferior and (3) prefer to avoid them. In this way, a
total score of 0–9 is obtained, where 0 represents no stigma, a score
of 1–6 represents mild to moderate stigma, and a score of 7–9
represents high stigma.11 Demographic data included age, sex,
marital status, level of education and employment status. Clinical
features included age of epilepsy onset, approximate number of all
seizures, approximate number of ‘major’ seizures to date, and time
period since the last seizure. In Croatian colloquial language, a
generalized tonic–clonic seizure (GTCS) is better known as a
‘major’ seizure, so in the questionnaire we used this term instead of
GTCS because we estimated that a proportion of subjects would
not understand the clinical term. However, we report results
pertaining to this question using the term GTCS. Number of
seizures was a multiple-choice question with the following
possible answers: Less than 5, 5–10, 10–50, 50–100 and More than
100, while the question about major seizures had the additional
choice – None. Age of epilepsy onset and time period since the last
seizure was free-response questions and these data were used to
calculate duration of epilepsy (in years) and seizure-free time
period (in days). When analysing education levels, subjects were
divided into three categories: (1) elementary school, (2) secondary
school and (3) college/school of higher education/university. When
analysing employment status, subjects were divided into two
categories: (1) unemployed/retired/disabled and (2) employed/in
education.
4. Simulation model of the ESS (smESS)
In the original version of the ESS, individuals are asked to
respond to the same three items, but instead of using a Likert scale
0–3, possible answers are dichotomous (either ‘yes’ or ‘no’). In this
way, the total score of the ESS is 0–3. We tried to make a simulation
model of this version of the ESS based on the assumption that asubject who reported not feeling stigmatised when completing the
rESS would choose the same answer when completing the ESS.
Based on this assumption, using the answers obtained from the
rESS, our smESS was calculated in the following way: if the answer
was 0 (not at all), it remained 0, and if it was either 1, 2 or 3 (yes
maybe, yes probably or yes deﬁnitely), it was scored as 1. In this
way, the total score of the smESS was 0–3.
5. Statistics
For statistical analysis, IBM SPSS Statistics, Version 20.0 was
used. Evaluation of the internal consistency of the scale was
estimated by Cronbach’s a test. Groups of subjects having no
stigma, mild-to-moderate stigma and severe stigma were com-
pared to ﬁnd differences in clinical and demographic character-
istics using analysis of variance and the x2 test, as appropriate. The
analysis was performed separately using the smESS, and the results
were compared with the ones using the rESS. For the multiple
regression analysis, a stepwise model was used to determine the
most signiﬁcant variables among independent variables that were
expected to have an inﬂuence on the total stigma scale score: age,
age of epilepsy onset, duration of epilepsy and seizure-free period
as continuous variables; sex, marital status and employment
status as dichotomous variables and level of education, number of
seizures and number of ‘major’ seizures as ordinal variables. Values
of p < 0.05 were considered signiﬁcant.
6. Results
Questionnaires were obtained from 310 subjects. None of the
subjects who were asked to ﬁll in the questionnaire refused to do
so, but 12 (4%) failed to respond to at least one of the items on the
stigma scale, so analysis was done on 298 subjects. Some of the
respondents also failed to adequately answer one or more of the
remaining questions, with the question about time since last
seizure producing the most frequently missing or inadequate
answers (32/298). These data, along with demographic and clinical
characteristics, are shown in Table 1.
Internal consistency of the rESS was 0.887.
In total, 159 subjects (53%) reported feeling stigmatised, with
136 (45%) mild to moderately and 23 (8%) highly. Frequency of
subjects feeling stigmatised did not differ signiﬁcantly between
the three outpatient centres (Centre No. 1: 51% of 76 subjects,
Centre No. 2: 53% of 91 subjects, Centre No. 3: 54% of 131 subjects).
Feelings of stigma were associated with age 50 years
(x2 = 6.435, df = 2, p = 0.040), younger age of epilepsy onset
(F(2,289) = 4.635, p = 0.010), more than 50 seizures to date
(x2 = 11.536, df = 2, p = 0.003), experiencing GTCS seizures
(x2 = 7.085, df = 2, p = 0.029) and a shorter seizure-free period
(F(2,264) = 3.420, p = 0.034) (Table 2). No statistically signiﬁcant
association was found between stigma and sex, marital status,
level of education, employment status or duration of epilepsy.
When multiple stepwise regression was performed, a signiﬁ-
cant model emerged (F(1,237) = 15.329, p < 0.001, adjusted
R2 = 0.057), with only one signiﬁcant variable – number of seizures
to date (Beta = 0.246), i.e. subjects who experienced more seizures
had higher levels of stigma.
By adapting the obtained data into the smESS as described in
Methods, associations of stigma score with more than 50 seizures
to date (x2 = 8.784, df = 3, p = 0.032), GTCS (x2 = 7.896, df = 3,
p = 0.048) and a shorter seizure-free period (F(3,263) = 3.367,
p = 0.019) remained signiﬁcant, while signiﬁcant associations with
age 50 years (x2 = 5.649, df = 3, p = 0.130) and younger age of
epilepsy onset (F(3,288) = 1.538, p = 0.205) were lost (Table 3).
Internal consistency of the smESS was slightly lower than for the
rESS, at 0.849.
Table 1
Baseline demographic and clinical characteristics.
N (number of subjects) 298
Age (years) 45 (16.3)a
Range 17–82
Sex
Male 135 (45%)
Female 162 (55%)
Marital status
Single 95 (32%)
Married/cohabiting 160 (54%)
Divorced 31 (11%)
Widowed 9 (3%)
Level of education
Elementary School 51 (18%)
Secondary School 176 (60%)
College/School of higher education 20 (7%)
University 24 (8%)
Still in education 21 (7%)
Employment status
Still in education 27 (9%)
Employed 79 (27%)
Unemployed (searching for work) 63 (22%)
Disabled 69 (24%)
Retired 53 (18%)
Age of epilepsy onset (years) 25 (17.8)a
Duration of epilepsy (years) 20 (14.8)a
Number of seizures to date
Less than 5 89 (31%)
5–10 49 (17%)
10–50 53 (19%)
50–100 35 (12%)
More than 100 61 (21%)
Number of GTCS to date
None 78 (27%)
Less than 5 94 (33%)
5–10 51 (18%)
10–50 26 (9%)
50–100 17 (6%)
More than 100 19 (7%)
Seizure-free time period 1079 (1743)a
6 months 120 (45%)
6–12 monthsb 28 (10%)
1–2 yearsb 32 (12%)
2–5 yearsb 37 (14%)
5–10 yearsb 32 (12%)
10 years or more 18 (7%)
Number of missing data: (age) 0, (sex) 1, (marital status) 3, (education) 6,
(employment) 7, (age of epilepsy onset) 6, (number of seizures) 11, (number of
‘‘major’’ seizures) 13, (time since last seizure) 31.
a Results are shown as mean (standard deviation) days.
b Category deﬁned as >lower limit and upper limit.
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In most studies of epilepsy stigma, the original version of the
ESS from 1992 was used,3,7,8,16,19–22 while in our research we
applied the rESS, as used in subjects from the SANAD trial.17,18
These data regarding stigma of patients with new onset epilepsy
from the SANAD trial were published in 2011.11 In our research, the
Croatian translation of the rESS proved to have good validity, with
high internal reliability.
Our results have shown that in Croatia, the frequency of stigma
among patients with epilepsy treated in hospital-based epilepsy
services (53%) is similar to the frequency in some other European
countries, although it is difﬁcult to make a direct comparison due
to the methodological differences in subject selection. In several
large European studies, subjects were selected from supportgroups or from outpatient neurology clinics (stigma frequency
46%15 and 51%,6 respectively), and in a study sample similar to ours
(a hospital-based epilepsy service) in Bulgaria, frequency of stigma
was 43.62% and 4.7%, depending on whether the patients had
pharmaco-refractory or pharmaco-sensitive epilepsy.7 Further-
more, although the subject groups were considerably different
regarding the duration of epilepsy, our ﬁgures were very similar to
those of Taylor et al.,11 where the frequency of stigma was 54%
(47.3% mild-moderate stigma, 6.1% high stigma). Even though the
possibility of direct comparison is limited, it seems that epilepsy
stigma in Croatia is not considerably different than in some other
European countries. This is in accordance with complementary
studies that showed that public prejudices towards people with
epilepsy in Croatia are generally not greater than in Western
European countries.23–28
According to our research, several clinical and demographic
factors are associated with stigma: younger age, earlier age of
epilepsy onset, more than 50 seizures to date, experienced GTCSs
and shorter seizure-free time period. Although the association of
age with stigma did not prove signiﬁcant using analysis of
variance, when we divided the subjects into two groups with age of
50 years as a limit, as Taylor et al. did,11 a statistically signiﬁcant
difference was obtained, with younger subjects expressing higher
levels of stigma. Apart from chronological age, age at the onset of
epilepsy also seems to be an important factor, as younger age of
epilepsy onset was found to be a signiﬁcant factor for stigma in
several other studies.6,15 Associations of stigma with seizure type
and frequency have been reported previously.6,11,14,15,19,21 Two
studies also compared levels of stigma between subjects with and
without a 6-month clinical remission29 or a 2-year clinical
remission,19 and reported greater prevalence of stigma in subjects
who were not in remission. However, to the best of our knowledge,
this was the ﬁrst stigma study where detailed data on time period
since last seizure was obtained (subjects with more recent seizures
usually responded in terms of days, weeks or months) and where
this variable was signiﬁcantly associated with stigma, i.e., subjects
with greater degrees of stigma had progressively shorter seizure-
free periods.
In an attempt to ﬁnd the most important factor for stigma
among the ones listed, multiple regression was performed. Our
model, although statistically signiﬁcant, accounts for only a small
proportion of the variance of stigma score (adjusted R2 = 0.057).
The reason for this could be that we used a relatively small number
of predictor variables, compared with other stigma studies with
somewhat better predictive ability models.6,11,16 Some of these
studies reported that the contribution of clinical and demographic
factors to stigma is relatively small compared with psychosocial
variables.14 Among the former, seizure frequency seems to be the
most dominant,14,15,19 which is in accordance with the most
important factor found in our study – number of seizures
experienced to date. The relative contribution of the most
important factors for stigma also seems to vary between different
European countries.6,15 Results of our study, as well as those by
others,3,7,8,16,19–22 lead to the conclusion that stigma is a
multifactorial condition with clear cross-cultural differences and
that future studies should take into account the possibility of
additional factors. Identifying and understanding these factors is
crucial to intervention studies aimed at reducing stigma; if the
factors that contribute to stigma are not identiﬁed they cannot be
targeted.
Although further research leading to a better understanding of
the factors contributing to stigma can be expected, the current
insights can already have signiﬁcant clinical implications. Being
aware of these factors makes it possible to actively search for
individuals who might be feeling a high level of stigmatisation,
where the rESS or the ESS could have a leading role. After detection
Table 2
Relationship between stigma scale scores and demographic and clinical factors.
rESS score
0 1–6 7–9 p-Value
Age (mean  SD years) 46.97  17.42 43.24  15.79 40.17  9.43 0.062a
Age (years)
50 79 92 18 0.040b
>50 61 43 5
Sex
Male 63 57 15 0.123b
Female 76 78 8
Marital status
Married/cohabiting 83 68 9 0.076b
Not married 54 67 14
Level of education
Elementary school 24 24 3 0.362b
Secondary school 86 77 13
College/university level 15 23 6
Employment status
Unemployed/retired/disabled 88 80 17 0.523b
Employed/in education 50 50 6
Age of epilepsy onset (mean SD years) 27.35  18.84 24.21  17.09 15.36  11.54 0.010a
Duration of epilepsy (mean SD years) 19.79  15.67 19.28  14.35 24.27  11.69 0.341a
N of seizures to date
<50 97 87 7 0.003b
>50 36 47 13
N of GTCS seizures to date
0 28 15 2 0.029b
1 or more 84 105 18
Seizure-free time period (mean  SD days) 1329  1808 970  1780 356  538 0.034a
Bolded are values of p<0.05.
a Analysis of variance.
b x2 test.
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be performed, as these are different in each person. Based on the
results, a personalized therapeutic approach could be developed,
including psychological, psychosocial and/or pharmacotherapeu-
tic strategies.
Limitations of our study include not taking into account the
possible inﬂuence of psychological factors and AEDs on felt stigma,
as the independent contribution of these factors to stigma has beenTable 3
Comparison of signiﬁcant associations of demographic and clinical factors with stigma
rESS score 
0 1–6 7–9 p-Value 
Age
50 years 79 92 18 0.040a
>50 years 61 43 5 
Age of epilepsy onset
Mean (years) 27.35 24.21 15.36 0.010b
SD (years) 18.84 17.09 11.54 
N of seizures to date
<50 97 87 7 0.003a
>50 36 47 13 
N of GTCS seizures to date
0 28 15 2 0.029a
1 or more 84 105 18 
Seizure-free time period
Mean (days) 1329 970 356 0.034b
SD (days) 1808 1780 538 
Bolded are values of p<0.05.
a x2 test.
b Analysis of variance.conﬁrmed in previous research. Taylor et al.11 found that PWE who
reported experiencing higher levels of felt stigma were more likely
to be classiﬁed as clinically anxious (62.5% vs. 17.3%) and
depressed (47.9% vs. 6.6%). Also, a moderate correlation was
found between depression and frequency and severity of
stigmatization.7 Associations of stigma with AEDs have been
shown to be related to their side-effects6 and the use of
polytherapy.7,14,15 It should also be acknowledged that this is, using the rESS and smESS.
smESS score
0 1 2 3 p-Value
79 28 25 57 0.130a
61 13 10 25
27.35 22.39 24.17 16.48 0.205b
18.84 13.17 20.77 1.83
97 31 20 43 0.032a
36 11 15 34
28 6 4 7 0.048a
84 29 29 65
1329 1386 406 839 0.019b
1808 2056 862 1674
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sample size. Further studies should be performed before our data
are generalized to all adult persons with epilepsy in Croatia.
Apart from the main aims of this study, we tried to make a
contribution to the choice of scale – the original ESS or the revised
version. So far, the ESS has been proved to be a suitable
international instrument for diagnosing epilepsy stigma, and its
conciseness makes it appropriate for everyday clinical practice.
Although we are aware of the fact that a simulation model cannot
replace true data acquisition and its analysis, the results of our
model point to the possibility that the rESS might be more sensitive
in the detection of factors contributing to stigma. In future, a larger
study, preferably using both scales, is needed to verify this thesis,
based on data presented in this paper.
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